KR102639432B1 - Medicinal suture coated with plant-derived polydeoxyribonucleotide and method for manufacturing the same - Google Patents

Abstract

One aspect of the present invention is a suture substrate; and a coating layer formed on at least a portion of the surface of the suture base and containing polydeoxyribonucleotide (PDRN) derived from plant callus extract. It provides a medical suture and a method of manufacturing the same.

Description

Medical suture coated with plant-derived polydeoxyribonucleotide and method for manufacturing the same {MEDICINAL SUTURE COATED WITH PLANT-DERIVED POLYDEOXYRIBONUCLEOTIDE AND METHOD FOR MANUFACTURING THE SAME}

The present invention relates to a medical suture coated with plant-derived polydeoxyribonucleotide and a method for manufacturing the same.

A suture is a thread or similar material used to connect or close damaged muscles, blood vessels, nerves, tissues, or wounds or surgical incisions.

Sutures can be divided into synthetic sutures and natural sutures depending on the raw materials. Depending on whether they are absorbed in the body, absorbable (degradable) sutures, which naturally decompose and are removed after a certain period of time after being sutured to the wound area, and the sutured tissue of the wound area. It can be classified as a non-absorbable (non-degradable) suture that does not decompose even after being sutured, so the suture must be removed through reoperation.

One of the important considerations in procedures using sutures is that the suture must be firmly maintained and fixed at the treatment site to ensure that the suture, tissue adhesion, support, and fixation effect is stable and long-lasting, and that the suture must not be released arbitrarily. A solid finish and treatment is required.

Polydioxanone (PDO) suture, a synthetic polymer, is widely used as an absorbable suture. However, when polydioxanone suture is used as a material for medical and/or surgical procedures, there are problems such as deterioration of physical properties due to lower stability against body fluids compared to existing non-absorbable sutures, which limits its use.

In addition, when used as a suture for internal surgery and/or lifting on facial skin, tissue rejection may occur due to a foreign body reaction in the early stages after suture and/or insertion, and in the mid to long term, decomposition residues may be absorbed, Side effects such as impeded excretion may occur. In particular, when absorbable sutures applied in plastic surgery lifting procedures cause these side effects, not only is it difficult for patients to expect the intended cosmetic effect, but there is also the problem of wounds, scars, and traces of the procedure remaining at the treatment site.

In response, technologies that use ingredients with antibacterial and anti-inflammatory properties or additives to improve mechanical properties are continuously being developed when manufacturing absorbable sutures. For example, Korean Patent No. 10-1586212, Korean Patent Publication No. 10-2019-0116647, and Korean Patent Publication No. 10-2019-0012958 contain ingredients such as DNA fragment mixture and polydeoxyribonucleotide (PDRN). Disclosed is a suture coated on the surface, and that the cell regeneration ability and lifespan of the suture can be improved through this.

However, since PDRN, a functional material used in coatings, is generally obtained from the semen of fish such as salmon and trout, the period in which it can be secured is limited to the fish's spawning season, which poses a problem of smooth supply and demand. In addition, it is difficult to secure large quantities of the same species to maintain and manage the quality of raw materials, and the mixture of DNA fragments derived from animals may contain harmful substances such as viruses and heavy metals, which poses a safety problem.

In response, Korean Patent Publication No. 10-2014-0091456 and others disclose a method of producing a mixture of gene fragments having a certain range of molecular weight by separating a gene mixture from plant tissue and treating it physically, chemically, and biologically. However, before separating the genetic mixture, even if the raw materials such as broccoli are washed to remove foreign substances and treated with a solution containing salt and surfactant to remove impurities, contaminants and pesticides introduced during the growth process may remain. When recovering PDRN, there is a problem in that a large amount of organic solvent is used to selectively separate and remove cell wall components such as cellulose, lignin, suberin, and cutin.

The present invention is intended to solve the problems of the prior art described above. The purpose of the present invention is to diversify and expand the supply and demand of raw materials, ensure safety for the human body, have excellent skin regeneration ability, and prevent skin damage caused by hypersensitivity reactions. The aim is to provide a medical suture that can soothe flushing and a manufacturing method thereof.

One aspect of the present invention is a suture substrate; and a coating layer formed on at least a portion of the surface of the suture base and containing polydeoxyribonucleotide (PDRN) derived from plant callus extract.

In one embodiment, the suture substrate may be an absorbable suture.

In one embodiment, the plant may be one selected from the group consisting of ginseng head, main root, centella asiatica root, and a combination of two or more of these.

In one embodiment, the coating layer may further include a binder made of a water-soluble polymer.

In one embodiment, the water-soluble polymer may be one selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylamide, polyhydroxyethyl methacrylate, and combinations of two or more thereof.

Another aspect of the present invention includes the steps of (a) inoculating pretreated plant material into MS (Murashige & Skoog) medium to induce and cultivate callus; (b) treating the callus with enzymes; (c) obtaining a callus extract by treating the product of step (b) with an extraction solvent; (d) separating PDRN by applying ultrasound to the callus extract; (e) preparing a coating solution by dissolving the PDRN in a solvent; and (f) applying the coating solution to the suture base and drying it.

In one embodiment, the plant raw material may be one selected from the group consisting of ginseng head, taproot, centella asiatica root, and a combination of two or more thereof.

In one embodiment, the MS medium may contain 2,4-dichlorophenoxyacetic acid and kinetin.

In one embodiment, the enzyme may include ribonuclease and proteinase.

In one embodiment, step (c) includes: (c1) treating the product of step (b) with a first extraction solvent to obtain a first callus extract; And (c2) treating the product of step (c1) with a second extraction solvent different from the first extraction solvent to obtain a second callus extract.

In one embodiment, the first and second extraction solvents may each include one selected from the group consisting of chloroform, alcohol with 1 to 6 carbon atoms, and combinations of two or more thereof.

In one embodiment, the concentration of PDRN in the callus extract may be 80 to 120 μg/mL.

In one embodiment, the ratio of the weight of the PDRN to the weight of the callus may be 0.03 to 0.1%.

In one embodiment, the coating solution may further include a binder made of a water-soluble polymer.

In one embodiment, the concentration of the binder in the coating solution may be 0.1 to 3% (w/v).

In one embodiment, the water-soluble polymer may be one selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylamide, polyhydroxyethyl methacrylate, and combinations of two or more thereof.

In one embodiment, the solvent is water, alcohol having 1 to 6 carbon atoms, methoxyethanol, ethoxyethanol, lactone, acetonitrile, n-methyl-2-pyrrolidone (NMP), formic acid, nitromethane, acetic acid. , dimethyl sulfoxide, and a combination of two or more thereof.

A medical suture according to one aspect of the present invention includes a suture base; and a coating layer formed on at least a portion of the surface of the suture base and containing polydeoxyribonucleotide (PDRN) derived from plant callus extract, thereby diversifying the raw materials for obtaining PDRN from conventional animals to plants, It can be expanded to stabilize supply and demand, ensure safety for the human body, have excellent skin regeneration ability, and effectively calm the flushing phenomenon caused by hypersensitivity reactions.

The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the configuration of the invention described in the detailed description or claims of the present invention.

Hereinafter, the present invention will be described. However, the present invention may be implemented in various different forms and is not limited to the embodiments described herein.

Throughout the specification, when a part is said to be “connected” to another part, this includes not only cases where it is “directly connected,” but also cases where it is “indirectly connected” with another member in between. . In addition, when a part is said to “include” a certain component, this does not mean that other components are excluded, but that other components can be added, unless specifically stated to the contrary.

medical suture

One aspect of the present invention is a suture substrate; and a coating layer formed on at least a portion of the surface of the suture base and containing polydeoxyribonucleotide (PDRN) derived from plant callus extract.

The suture base may include at least one of an absorbable suture and a non-absorbable suture, preferably an absorbable suture, but is not limited thereto.

The absorbable suture may be divided into natural absorbable suture and synthetic absorbable suture, the natural absorbable suture may be catgut, chromic catgut, etc., and the synthetic absorbable suture may be polyglycolic acid, polydioxa. It may be rice paddy (PDO), etc., but is not limited thereto.

The non-absorbable suture may be divided into natural non-absorbable suture and synthetic non-absorbable suture, the natural non-absorbable suture may be silk, etc., and the synthetic non-absorbable suture may be polyester, polypropylene, polyamide, poly It may be tetrafluoroethylene, but is not limited thereto.

The coating layer may be formed on at least part of the surface of the suture substrate, preferably the entire surface, and may include polydeoxyribonucleotide (PDRN) derived from plant callus extract.

The PDRN, which is a functional material included in the coating layer, is generally obtained from the semen of fish such as salmon and trout, so the period for securing it is limited to the spawning season of fish, and there is a problem of smooth supply and demand. In addition, it is difficult to secure large quantities of the same species to maintain and manage the quality of raw materials, and the mixture of DNA fragments derived from animals may contain harmful substances such as viruses and heavy metals, which poses a safety problem.

In contrast, the coating layer contains PDRN derived from plant callus extract, thereby converting, diversifying, and expanding animal tissues such as fish testes and fish semen, which were previously used as raw materials for obtaining PDRN, into plant tissues, thereby further stabilizing supply and demand. It is safe for the human body, has excellent skin regeneration ability, and can effectively soothe flushing caused by hypersensitivity reactions.

The plant may be one selected from the group consisting of the head of ginseng, the main root, the root of Centella asiatica, and a combination of two or more thereof, preferably considering quantitative aspects such as the yield of the PDRN and qualitative aspects such as purity. Therefore, it may be the head of ginseng and/or the root of Centella asiatica, but is not limited thereto.

The coating layer may further include a binder made of water-soluble polymer. The term "binder" used herein has the property of adhering well to the suture substrate, so it can improve the bonding force between the coating layer and the suture substrate, and provides bonding force between the PDRN included in the coating layer to the PDRN. This refers to a material that prevents arbitrary detachment from the suture substrate and thus maintains efficacy based on the PDRN in the area to which the medical suture is applied.

The binder may be a water-soluble polymer with excellent biocompatibility and safety. The water-soluble polymer may be one selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylamide, polyhydroxyethyl methacrylate, and combinations of two or more thereof, preferably polyvinyl It may be pyrrolidone, but is not limited thereto. The “combination” of the water-soluble polymer means a mixture of two or more water-soluble polymers and/or a copolymer thereof.

When the water-soluble polymer is used as the binder, an organic solvent may not be used when preparing a coating solution for forming the coating layer, and the coating layer containing the PDRN may be coated with a uniform thickness.

Manufacturing method of medical suture

Another aspect of the present invention includes the steps of (a) inoculating pretreated plant material into MS (Murashige & Skoog) medium to induce and cultivate callus; (b) treating the callus with enzymes; (c) obtaining a callus extract by treating the product of step (b) with an extraction solvent; (d) separating PDRN by applying ultrasound to the callus extract; (e) preparing a coating solution by dissolving the PDRN in a solvent; and (f) applying the coating solution to the suture base and drying it.

Callus can be induced and cultured by inoculating the plant material pretreated in step (a) into MS (Murashige & Skoog) medium. The plant raw material may be one selected from the group consisting of ginseng head, taproot, centella asiatica root, and a combination of two or more thereof, and preferably, quantitative aspects such as yield of the PDRN and qualitative aspects such as purity Considering this, it may be the head of ginseng and/or the root of Centella asiatica, but is not limited thereto. The pretreatment may be performed by a process of washing and disinfecting the plant raw material and, if necessary, cutting it into a required size. The cleaning and disinfection may be performed by physical, chemical, or biological methods, and preferably, may be performed by chemical methods using water, solvents, disinfectants, etc., but are not limited thereto.

The MS medium is a widely used medium for cultivating and growing plant tissues, and may further contain organic additives such as nitrate, agar, sugar, vitamins, and growth regulators. For example, the MS medium may contain 2,4-dichlorophenoxyacetic acid and kinetin. The 2,4-dichlorophenoxyacetic acid is a derivative of auxin and can act as a hormone for inducing callus during plant cell culture. The kinetin is a type of cytokinin, a type of plant hormone that promotes cell division, and can induce and promote the formation of plant callus together with the 2,4-dichlorophenoxyacetic acid.

The concentration of 2,4-dichlorophenoxyacetic acid in the MS medium may be 1 to 10 μM, preferably 2 to 8 μM, more preferably 3 to 6 μM, and the concentration of kinetin may be 0.1 to 6 μM. It may be 1 μM, preferably 0.2 to 0.8 μM, more preferably 0.3 to 0.6 μM.

In step (b), the callus may be treated with enzymes. The enzyme may include ribonuclease (RNase) and proteinase.

The ribonuclease can decompose nucleic acids in the callus and convert them into DNA fragments (fragments) such as oligonucleotides and single nucleic acids. The proteinase can generally be used to break down proteins and remove contamination from the callus. When the proteinase is added to the callus, nucleases (DNase and/or RNase) that can degrade DNA or RNA during the purification process can be quickly deactivated, thereby destroying proteins and releasing nucleic acids in the callus. can be applied to

In step (c), a callus extract can be obtained by treating the product of step (b) with an extraction solvent. In step (c), the product of step (b), or subsequent intermediates and/or products, is immersed in the extraction solvent, centrifuged, and the supernatant is recovered (recovered) or discarded. The process may be repeated two or more times.

Step (c) includes the step of (c1) treating the product of step (b) with a first extraction solvent to obtain a first callus extract; And (c2) treating the product of step (c1) with a second extraction solvent different from the first extraction solvent to obtain a second callus extract.

The first and second extraction solvents may each include one selected from the group consisting of chloroform, alcohol with 1 to 6 carbon atoms, and combinations of two or more thereof.

For example, in step (c1), the product of step (b) may be treated with a mixed solvent containing chloroform and isoamyl alcohol in a volume ratio of 10 to 30:1, then centrifuged, and the supernatant may be recovered. , in step (c2), the supernatant recovered in step (c1) may be treated with isopropanol, then centrifuged, the supernatant may be discarded, and the precipitate may be recovered. Additionally, the precipitate recovered in step (c2) may be treated with ethanol, then centrifuged, the supernatant may be discarded, and the remaining solution may be dried to recover the solid content.

In step (d), PDRN can be separated by applying ultrasound to the callus extract. At this time, the concentration of PDRN in the callus extract is 80 to 120 μg/mL, preferably 85 to 120 μg/mL, more Preferably, it may be 100 to 120 μg/mL. If the concentration of the PDRN in the callus extract is less than 80 μg / mL, the content of the PDRN in the coating layer is small, making it difficult to implement the intended effect, and if it is more than 120 μg / mL, the solubility and dispersibility of the PDRN in the coating solution will decrease. You can.

The ratio of the weight of the PDRN isolated and recovered in the step (d) to the weight of the callus induced and cultured in the step (a), that is, the yield (%) of the PDRN based on the weight of the callus It may be 0.03 to 0.1%, preferably 0.04 to 0.1%, more preferably 0.05 to 0.1%.

In step (e), a coating solution can be prepared by dissolving the PDRN in a solvent. The coating solution may further include a binder made of water-soluble polymer. The types, effects, etc. of the water-soluble polymer are the same as described above.

The concentration of the PDRN in the coating solution may be 0.5 to 5% (w/v), preferably 1 to 3% (w/v), more preferably 1 to 2.5% (w/v), , the concentration of the binder may be 0.1 to 3% (w/v), preferably 0.3 to 1.5% (w/v). If the concentration of the PDRN in the coating solution is less than 0.5% (w/v), the content of the PDRN in the coating layer is small, making it difficult to achieve the intended efficacy, and if it is more than 5% (w/v), the PDRN in the coating solution is difficult to achieve. Solubility and dispersibility may decrease. In addition, if the concentration of the binder in the coating solution is less than 0.1% (w/v), the binding force between the coating layer, the suture substrate, and the PDRN in the coating layer may be reduced, and if it is more than 3% (w/v), the binding force between the PDRN in the coating layer may be reduced. Since the content of the binder is relatively large compared to the PDRN, diffusion to the target site and the resulting efficacy may be inhibited by excessive binding of the PDRN.

The solvent is water, alcohol with 1 to 6 carbon atoms, methoxyethanol, ethoxyethanol, lactone, acetonitrile, n-methyl-2-pyrrolidone (NMP), formic acid, nitromethane, acetic acid, dimethyl sulfoxide and these. It may be one selected from the group consisting of a combination of two or more of the following. The alcohol having 1 to 6 carbon atoms may be, for example, methanol, ethanol, propanol, butanol, etc., but is not limited thereto.

When the coating solution contains the water-soluble polymer, the solvent may be water, and, if necessary, may further include a hydrophilic organic solvent such as an alcohol having 1 to 6 carbon atoms. In addition, when the coating solution does not contain the water-soluble polymer, the solvent may be a hydrophilic organic solvent such as an alcohol having 1 to 6 carbon atoms, and, if necessary, may further include water and/or other organic solvents. .

In step (f), the coating solution is applied to the suture base and then dried to finally obtain a medical suture coated with the PDRN on at least a portion of the surface of the suture base.

The application may be accomplished by means such as dip, spray, roll, bar, etc., and preferably, the suture base is applied to the coating solution by dip. This may be accomplished by impregnating for a set time, but is not limited to this.

Through the drying, the solvent in the coating solution can be removed and the PDRN can be bonded to the surface of the suture base, and the PDRN can be bonded to each other. Conditions required for the drying, such as temperature and time, can be appropriately controlled considering the concentration of the coating solution, the thickness and/or area of the coating layer, the boiling point of the solvent, etc.

Hereinafter, embodiments of the present invention will be described in detail.

Examples 1 to 2

1. Cleaning and disinfection (pretreatment)

The main root of ginseng was washed with water and cut into pieces about 5cm long. The cut taproot was immersed in 70% ethanol for 30 seconds, and then immersed in a 6% sodium hypochlorite solution containing 0.1% Tween-20 to disinfect the surface of the taproot for 15 minutes. The disinfected taproot was washed with water, dipped in 70% ethanol for 30 seconds, and then dipped in a solution containing 3% sucrose and 1 mg/mL of 2,4-dichlorophenoxyacetic acid for about 30 minutes.

2. Callus culture

Samples were obtained by drying the pretreated taproot on sterilized filter paper to remove moisture and cutting it into pieces of 2 to 3 mm ² in size. The sample was inoculated into MS medium (pH 5.8) containing 2,4-dichlorophenoxyacetic acid, kynetin, sucrose, and Gelrite, and incubated at 20-26°C in dark conditions for 4-8 weeks. Callus was induced by culturing. The composition of the MS medium is shown in Table 1 below.

ingredient Content (concentration) MS medium (Murashige & Skoog medium) 4.66g/L 2,4-dichlorophenoxyacetic acid 4.5μM kinetin 0.46μM sucrose 30g/L Gelite 1.4g/L

The induced callus was subcultured at intervals of approximately 2 to 4 weeks and proliferated. The induced callus was cut into small pieces, inoculated into liquid MS medium excluding gelite, and cultured at 25°C to maintain continuous growth.

3. PDRN extraction

5 g of ginseng main root callus was ground in a mortar and pestle using liquid nitrogen. Liquid nitrogen was continuously added and repeated until the Myeongwolcho callus was completely pulverized. After measuring the mass of the pulverized ginseng root callus powder, it was treated with 0.5 mL of CTAB (Cetyltrimethyl ammonium bromide) buffer per 100 mg of callus, mixed, and left in a constant temperature water bath at 60°C for 30 minutes.

After centrifugation at 14,000g for 5 minutes, the supernatant was recovered. 5 μL of RNase A solution was added to the supernatant and left at 37°C for 30 minutes. Afterwards, 50 μL of Proteinase K solution with a concentration of 20 mg/mL was added and left at 37°C for 60 minutes. Equal amounts of chloroform and isoamyl alcohol were added and mixed at a volume ratio of 24:1, centrifuged at 14,000 g for 5 minutes, and the supernatant was recovered.

Refrigerated isopropanol was added in an amount 0.7 times the amount of the recovered supernatant, mixed, and left at 20°C for 20 minutes. After centrifugation at 14,000g for 10 minutes, the supernatant was discarded, and refrigerated 70% ethanol was added to the precipitate.

After centrifugation at 14,000 g for 1 minute, the supernatant was discarded, the remaining solution was dried, and 100 μL of purified water was added. Afterwards, ultrasound was applied to obtain a solution in which polydeoxyribonucleotide (PDRN) was fractionated (hereinafter referred to as PDRN solution). The PDRN solution was dried and then pulverized to prepare a powdery PDRN sample (hereinafter referred to as PDRN powder). Two PDRN powders were obtained in the same manner as described above, and each of them was named Example 1 and 2.

Examples 3 to 5

Three PDRN powders were prepared in the same manner as Example 1, except that the main root part of ginseng was replaced with the brain head part, and each of them was named Examples 3 to 5.

Examples 6 to 10

Five PDRN powders were prepared in the same manner as Example 1, except that the main root part of ginseng was replaced with the root part of Centella asiatica, and each of them was named Examples 6 to 10.

Experimental Example 1

The PDRN powder prepared in Examples 1 to 10 was dissolved in a buffer (pH 8.0) containing 10mM Tris-HCl and 1mM EDTA to prepare a sample with a concentration of 1mg/mL.

The absorbance of the sample was measured using a Nanodrop (Thermo ND-100 Nanodrop Spectrophotometer) device, and the concentration and yield of PDRN in the sample were calculated based on the measured absorbance. The results are shown in Tables 2 and 3 below. It was.

division PDRN concentration
(μg/mL) A260 A280 A260/A280 A260/A230 Example 1 116.37 2.33 1.23 1.89 2.34 Example 2 104.81 2.10 1.11 1.89 2.33 Example 3 115.01 2.30 1.22 1.88 2.33 Example 4 87.35 1.75 0.93 1.87 2.28 Example 5 100.51 2.01 1.08 1.87 2.31 Example 6 88.32 1.77 0.93 1.89 2.33 Example 7 88.95 1.78 0.95 1.88 2.33 Example 8 102.94 2.06 1.09 1.89 2.34 Example 9 103.67 2.07 1.11 1.87 2.30 Example 10 88.88 1.78 0.96 1.86 2.28

-A230: Absorbance of phenol, EDTA, and other organic substances at a wavelength of 230 nm

-A260: Absorbance of PDRN for 260nm wavelength

-A280: Absorbance of proteins (trypsin, tryptophan, etc.) at a wavelength of 280 nm

division Callus powder weight (mg) Nucleic acid total weight (mg) PDRN total weight (mg) Nucleic acid yield based on raw material (%) PDRN yield based on nucleic acid (%) PDRN yield based on raw material (%) Example 1 5,200 2.93 1.71 0.056 58.36 0.033 Example 2 4,900 2.22 1.63 0.045 73.42 0.033 Example 3 4,500 3.31 2.42 0.074 73.11 0.054 Example 4 6,000 3.58 2.46 0.060 68.72 0.041 Example 5 6,800 3.59 2.83 0.053 78.83 0.042 Example 6 4,700 2.62 2.26 0.056 86.26 0.048 Example 7 5,000 2.38 1.87 0.048 78.57 0.037 Example 8 5,300 3.37 1.84 0.064 54.60 0.035 Example 9 6,200 2.91 2.35 0.047 80.76 0.038 Example 10 5,500 2.83 1.69 0.051 59.72 0.031

-Nucleic acid yield based on raw materials (%)={(total nucleic acid weight)/(callus powder weight)}*100

-PDRN yield based on nucleic acid (%)={(Total PDRN weight)/(Total nucleic acid weight)}*100

-PDRN yield based on raw materials (%)={(PDRN total weight)/(callus powder weight)}*100

Referring to Table 1 above, the concentration of PDRN derived from ginseng main root, cerebellum, and centella asiatica root callus is each 85 μg/mL or more, preferably 100 μg/mL or more, and in particular, some of the ginseng main root and eurycephalus callus. The concentration of one PDRN was found to be over 110 μg/mL, indicating that a sufficient amount of PDRN could be obtained to coat the surface of the suture and exert effective efficacy. In addition, the A260/A280 value of the samples according to Examples 1 to 10, that is, PDRN powder, is 1.8 or more, preferably 1.85 or more, and the A260/A230 value is 2.2 or more, preferably 2.3 or more, so that the sample It can be seen that the purity of PDRN is also at a good level.

Meanwhile, looking at the yield of PDRN finally obtained based on the weight of the callus powder used to extract PDRN, the yield when using ginseng callus callus is 0.04% or more compared to when using ginseng main root callus, preferably, It was relatively high at over 0.05%, and even when using Centella asiatica root callus, a maximum yield of over 0.045% was recorded. In terms of this yield and the ease of supply of raw materials, the productivity of PDRN is also at a similar level to that of PDRN derived from animal tissue. can be seen.

Manufacturing Example 1

The PDRN powder obtained in Example 2 was added to 99.5% (w/v) methanol, and then stirred at 1,500 rpm for 2.5 hours using a homogenizer to prepare a solution with a PDRN powder concentration of 2% (w/v). was manufactured.

Polydioxanone (PDO) sutures were immersed in the solution at room temperature of 25°C, stirred at a speed of 30 rpm for 1 hour to apply PDRN to the surface of the polydioxanone sutures, and then dried for 40 minutes using a drying oven. It was vacuum dried at ℃ for 4 hours. Finally, the surface of the suture was disinfected with ethylene oxide gas to prepare PDRN-coated suture.

Production example 2

PDRN-coated sutures were manufactured in the same manner as Preparation Example 1, except that the PDRN powder obtained in Example 3 was used instead of Example 2.

Production example 3

PDRN-coated sutures were manufactured in the same manner as Preparation Example 1, except that the PDRN powder obtained in Example 6 was used instead of Example 2.

Production example 4

After adding the PDRN powder and polyvinylpyrrolidone obtained in Example 3 to purified water, it was stirred at 1,500 rpm for 2.5 hours using a homogenizer so that the concentrations of PDRN powder and polyvinylpyrrolidone were 2% (w), respectively. /v) and 0.5% (w/v), a PDRN-coated suture was prepared in the same manner as Preparation Example 2, except that the solution was prepared.

Comparative Manufacturing Example 1

PDRN-coated suture was manufactured in the same manner as Preparation Example 1, except that PDRN powder obtained from salmon semen was used instead of Example 2.

Comparative Manufacturing Example 2

Sodium hyaluronate was added to 99.5% (w/v) methanol, and then stirred at 1,500 rpm for 2.5 hours using a homogenizer to prepare a solution with a sodium hyaluronate concentration of 15% (w/v). .

Polydioxanone (PDO) sutures were immersed in the solution at room temperature of 25°C, stirred at a speed of 100 rpm for 1 hour, and sodium hyaluronate was applied to the surface of the polydioxanone sutures, followed by using a drying oven. It was vacuum dried at 60°C for 4 hours. Finally, the surface of the suture was disinfected with ethylene oxide gas to prepare a suture coated with sodium hyaluronate.

Experimental Example 2

The occurrence of facial flushing was observed in 10 patients each who underwent lifting procedures using each suture manufactured in the above Preparation Example and Comparative Preparation Example, and the results are shown in Table 4 below. In Table 4 below,

division Manufacturing Example 1 Production example 2 Production example 3 Production example 4 Comparative Manufacturing Example 1 Comparative Manufacturing Example 2 patient 1 ○ ○ ◎ ◎ ◎ △ patient 2 △ ◎ ○ ◎ ○ X patient 3 ○ ○ ◎ ○ ○ △ patient 4 ◎ ◎ ◎ ◎ ◎ X patient 5 ◎ ◎ ○ ◎ ○ △ patient 6 ○ ○ ◎ ◎ ◎ △ patient 7 ○ ◎ ○ ◎ ◎ X patient 8 ◎ ◎ ◎ ○ ◎ △ patient 9 △ ○ ○ ◎ ◎ △ patient 10 ○ ◎ ◎ ◎ ○ X

The description of the present invention described above is for illustrative purposes, and those skilled in the art will understand that the present invention can be easily modified into other specific forms without changing the technical idea or essential features of the present invention. will be. Therefore, the embodiments described above should be understood in all respects as illustrative and not restrictive. For example, each component described as single may be implemented in a distributed manner, and similarly, components described as distributed may also be implemented in a combined form.

The scope of the present invention is indicated by the claims described below, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be construed as being included in the scope of the present invention.

Claims (17)

suture substrate; and
A coating layer formed on at least a portion of the surface of the suture base and containing polydeoxyribonucleotide (PDRN) derived from a callus extract of the ginseng head. In the medical suture, comprising:
The medical suture is,
(a) Inducing and culturing callus by inoculating pretreated ginseng heads into MS (Murashige & Skoog) medium;
(b) treating the callus with enzymes including ribonucleases and proteinases;
(c) obtaining a callus extract by treating the product of step (b) with one selected from the group consisting of chloroform, alcohol with 1 to 6 carbon atoms, and combinations of two or more thereof;
(d) applying ultrasound to the callus extract to separate the PDRN solution, drying it, and pulverizing it to obtain PDRN powder;
(e) preparing a coating solution by dissolving the PDRN powder in one selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and a combination of two or more thereof; and
(f) applying the coating solution to the suture base and drying it;
The ratio of the weight of the PDRN powder to the weight of the callus is 0.04 to 0.1%,
Medical suture. According to paragraph 1,
The suture substrate is an absorbable suture, a medical suture. delete According to paragraph 1,
The coating solution is a medical suture, further comprising a binder made of a water-soluble polymer. According to clause 4,
The water-soluble polymer is a medical suture selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid, polyacrylamide, polyhydroxyethyl methacrylate, and combinations of two or more thereof. delete delete According to paragraph 1,
The MS medium contains 2,4-dichlorophenoxyacetic acid and kinetin, a medical suture. delete delete delete According to paragraph 1,
Medical suture, wherein the concentration of the PDRN powder in the callus extract is 80 to 120 μg/mL. delete delete According to clause 4,
Medical suture, wherein the concentration of the binder in the coating solution is 0.1 to 3% (w/v). delete delete